摘要
电压门控钠离子通道亚型Nav1.7在伤害性感觉神经元中高表达,是多种人类遗传性疼痛综合征的关键致病靶点。近年来,大量研究表明Nav1.7在炎性、神经病理性及伤害性刺激诱发的疼痛中具有重要作用。因此,靶向抑制Nav1.7是新型镇痛药研制的新策略和热点。本文介绍了Nav1.7的结构与功能、在疼痛中的调节作用,重点总结了临床试验中Nav1.7小分子抑制剂的开发进展,并对临床前Nav1.7高专一性抑制剂的开发进行了分析,以期为Nav1.7镇痛药物的开发提供参考。
The voltage-gated sodium channel subtype Navl.7 is highly expressed in nociceptive sensory neurons and is a key pathogenic target in several human hereditary pain syndromes.In recent years,a large number of studies have shown that Nav1.7 plays an important role in inflammatory,neuropathic,and nociceptive pain.Therefore,targeting Navl.7 is a new strategy and hotspot for the development of novel analgesics.This review introduces the structure and function of Navl.7,its regulatory role in pain,highlights the development progress of small-molecule Navl.7 inhibitors in clinical trials,and analyzes the preclinical development of highly specific Nav1.7 inhibitors,with a view to providing reference for the development of Nav1.7 analgesic drugs.
作者
韩蕊
蔡怡琳
郑晓彤
林凡祺
张凡
HAN Rui;CAI Yi-lin;ZHENG Xiao-tong;LIN Fan-qi;ZHANG Fan(College of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China)
出处
《药学学报》
CAS
CSCD
北大核心
2024年第9期2417-2428,共12页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(319009050)
中央高校基本科研业务费专项资金(2632023TD02).